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Abstract: New-onset refractory status epilepticus (NORSE) is associated with high
mortality, therapy resistant epilepsy (TRE) and poor cognitive and functional outcomes.
Some patients develop multifocal TRE, for whom surgery with a curative intention, is not
an option. In these patients, Vagus Nerve Stimulation (VNS) is performed as a palliative
treatment. We report the long-term outcomes regarding seizure frequency, functional and
cognitive outcome, and effectiveness of VNS in two patients with TRE as a consequence
of NORSE. In the first patient with cryptogenic NORSE, VNS implantation occurred
during the acute stage, probably contributing to the cessation of her status epileptic us.
However, in the long-term follow-up, the patient persisted with daily multifocal seizures.
In the second patient, VNS implantation was delayed to manage his epilepsy when the
NORSE, ultimately due to autoimmune encephalitis, had resolved. During long- term
follow-up, no reduction in seizure frequency was achieved. The current evidence
supporting the use of VNS in patients with TRE after NORSE warrants further
investigation.

Key words: Status epilepticus, autoimmune epilepsy, encephalitis, VNS, therapy
resistant epilepsy.

1. Introduction
New-onset refractory status epilepticus (NORSE) is a clinical presentation of
refractory status epilepticus (RSE) in previously healthy individuals, without an
acute structural, toxic, or metabolic cause 1 . In approximately 50% of cases the
etiology is unknown while in the other half, autoimmune encephalitis is the most
common cause 2 . No specific therapy is currently available for those patients;
therefore,

combinations

of antiseizure

medications

(ASMs), anesthetics,

immunotherapy and ketogenic diet are prescribed in the attempt to stop NORSE
3 . Furthermore,

few cases of acute implantation of Vagus Nerve Stimulator (VNS)

have been described 4 . Most treatment recommendations are based on expert
opinion.
NORSE is associated with high mortality and poor cognitive and functio na l
outcomes 2 . Around 40% of patients with NORSE develop epilepsy afterwards

2,3.

Some patients can develop bitemporal or multifocal therapy resistant epilepsy
(TRE), for whom surgery with a curative intention is not an option 5 . In these
patients the implantation of VNS is performed as a palliative treatment. Although
the general effectiveness of VNS has been described 6 , there is insufficient data
regarding its long-term outcomes in patients after NORSE.
We describe two patients who had NORSE and developed TRE epilepsy. The
VNS was implanted in the acute and chronic phase, respectively. The long- term
outcomes will be reviewed.
2. Cases Presentation
Patient 1
A 37-year-old woman, with an unremarkable medical history, was found
unconscious after a week of mild flu-like symptoms, including fever. She was

brought to the emergency department where a bilateral tonic-clonic seizure was
witnessed. Her disease progressed to multifocal RSE. Different ASMs and
anesthetics were prescribed without success. The initial work-up was done early
and was negative for structural, toxic, metabolic, and infectious etiologies.
Autoimmune encephalitis was proposed as a possible etiology and she completed
a course of corticosteroids, intravenous immunoglobulin (IVIG) and rituximab
weekly, while she was admitted to Intensive Care Unit (ICU). When the results
arrived, her complete autoimmune panel was negative. After 30 days of NORSE,
she had received two more doses of rituximab, but she persisted in Super-RSE
(SRSE). At that time, VNS was implanted, and rapid upwards titration of output
current was established, reaching 1.25mA in 48 hours and 1.75mA on the seventh
day. On the same day the SRSE was aborted. Additionally, on the seventh day she
completed three doses of rituximab without changes to her ASMs or anesthetics
during the preceding days. Even though NORSE was aborted, focal seizures, some
of which progressed to bilateral tonic-clonic seizures, persisted (Table 1). Six
doses of rituximab were given, and immunotherapy was continued as an
outpatient using azathioprine, without improvement of the seizure frequency. She
never experienced a seizure-free period and daily seizures occurred despite
different combinations of ASMs, VNS and azathioprine. After 1.5 years she was
admitted to the Epilepsy Monitoring Unit (EMU). Immune work-up was repeated
and was negative. Multifocal epilepsy due to NORSE of unknown etiology was
the final diagnosis. At the last follow-up, two years after onset of NORSE, she
persisted with daily focal seizure with impairment of awareness despite four
ASMs and high VNS parameters. Neuropsychological evaluation showed

moderate global cognitive and mild emotional involvement, affecting her social
life (Table 1).
Patient 2
A previously healthy 33-year-old man presented with RSE that progressed to
SRSE over a few days. His NORSE presentation was preceded by flu- like
symptoms, without fever, one week before the onset. The SRSE required
management in ICU and an extensive work-up was completed after which
structural, toxic, metabolic and infections causes were ruled out. Seventy- two
hours later the cause of SRSE had not yet been identified and the presentation was
consistent with NORSE. Simultaneously, seizure management was initiated using
different ASMs and anesthetics.

After six weeks, the SRSE was aborted.

However, due to a persistent state of confusion an autoimmune encephalitis was
considered, and immunotherapy was started. At that time, the autoimmune panel
revealed a positive anti-N-methyl-D-aspartate receptor (NMDAR) antibody in
CSF. Imaging studies and serum investigations were negative for a paraneoplastic
syndrome. The patient improved and 1.5 months after he was discharged home
with three ASMs, prednisone and azathioprine (Table 1). Eight months later,
when a taper of ASMs was trialed, the patient developed focal non-motor seizures
with impairment of awareness, which sometimes progressed to bilateral tonicclonic seizures. Despite different ASMs and immunosuppressive treatments, the
frequency of seizures worsened over time. Three years later, the patient was
investigated in the EMU and multiple independent bi-temporal seizures were
captured. Brain magnetic resonance imaging (MRI) showed bilateral mesial
temporal sclerosis (MTS) and cortical atrophy mainly in the left posterior
quadrant (Figure 1). A repeat autoimmune panel was negative. Azathioprine was

discontinued and VNS was proposed, which the patient declined. Over the
subsequent nine years, seizure frequency increased to up to twelve per month. At
that time, the patient reconsidered VNS, which was implemented with the
parameters increasing overtime. Eight months after the VNS implantation the
frequency of seizures improved reaching 2-3 per month. However, this was not
sustained. Two years after the implantation, the seizure frequency returned to 812 seizures per month. His neuropsychological assessment showed multifoca l
cognitive impairment, as well as poor quality of life (Table 1).

3. Discussion
We presented two patients with multifocal and bi-temporal TRE respectively, that
developed as a consequence of NORSE. In Patient 1, the clinical presentation was
compatible with febrile infection-related

epilepsy syndrome (a subtype of

NORSE) and the etiology was unknown despite an extensive work-up. In addition,
there was no clear response to immune-based therapies over time, which
potentially argues against an autoimmune etiology. For this patient, VNS was
implanted during the SRSE in an attempt to resolve the SRSE. In Patient 2, the
NORSE was eventually found to be caused by an anti-NMDAR antibody
encephalitis. In this second patient, VNS was implanted in a delayed manner to
manage escalating seizures, years after the NORSE had presented. In both
patients, the NORSE led to prolonged admissions to ICU and resulting in TRE.
The effectiveness of VNS in patients during NORSE and with epilepsy after
NORSE is unknown. A recent systematic review focused on the use of VNS in
the acute management of RSE and included 9 patients with NORSE. The analys is
reported that for 66% (6/9) of patients RSE ceased after the implantation of VNS

4 . The

systematic review included only case reports, which were the highest level

of available evidence for this rare condition. There was a clear relations hip
between VNS and cessation of RSE in only two cases 7,8 . A different report details
a patient whose implantation was considered successful, seizures recurred, and the
patient died 9 . In the other reports, it is unclear which of the multiple treatments
or a combination thereof were responsible for ceasing the NORSE 4,10 . In Patient
1 about whom we report, a rapid upwards titration of output current was completed
without side effects reaching a stimulation intensity of 1.75mA by the seventh
day, which coincided with cessation of status epilepticus. However, discrete
seizures persisted daily, and the patient developed epilepsy without a latent period
after NORSE. In this patient, no reduction in the frequency of seizures was
achieved overtime despite the combination of different ASMs, immunotherap y
and high parameters of VNS.
Even though in patient 2 the NORSE was due to autoimmune encephalitis, the
immunological study was negative in the post-NORSE stage, which may explain
the lack of response to chronic immunotherapy. At this stage, structural changes
(such as MTS, focal or diffuse cortical atrophy) would be the main mediators in
seizure production. In this patient the term "autoimmune-associated epilepsy",
that was recently proposed by the International League Against Epilepsy (ILAE),
is appropriate to highlight how other non-immune factors may play a role in postautoimmune encephalitis epilepsy

11 . In this

patient, the implantation of VNS was

late (nine years after NORSE) and although he experienced a significant reduction
(75%) in the frequency of seizures, this was not sustained overtime.
In our first patient, the VNS titration was fast, reaching 1.75 mA in one week; in
the second patient it was slow, reaching 2 mA in 8 months. The safety of rapid

titration is currently unknown, and several factors need to be considered to avoid
complications and reduce adverse effects. Notably, in the acute stages of NORSE
patients are sedated and unconscious and therefore less likely to experience side
effects.
The VNS implantation in TRE post NORSE has been described in three patients;
two patients with FIRES

5 , one

partial seizures (AERRPS)

12

with acute encephalitis with refractory repetitive

and only the last patient experienced a decrease in

the number of seizures of more than 50% in follow-up. The mechanisms how VNS
can improve NORSE are still unknown. An anti-inflammatory theory has been
proposed. Brain inflammation may play a role in increasing the hyperexcitability
during NORSE and VNS has shown to reduce levels in interleukins in patients
with TRE

4,5 .

The lack of response to VNS in the chronic stage for both of our

patients, could be explained by a lack of immunological role in the chronic stages
of their disease course. However, we do not know if our first patient would be
worse without VNS.
Furthermore, we have described the poor cognitive, emotional, and social
outcomes that developed our patients. Our findings show that the long-term effect
of NORSE leads to multifocal impairments across different cognitive domains,
which is likely to have a direct impact on quality of life.

4. Conclusion
NORSE has significant long-term morbidity, including therapy resistant epilepsy
and cognitive, emotional, and social consequences. Available treatments lack
effectiveness We describe two cases with TRE after NORSE, who underwent
VNS implantation. Although the VNS implantation was done at different points

in the illness trajectory (acute and chronic phase of NORSE), we show the longterm outcomes after the implantation of VNS, which is still unknown and warrants
further investigation. Our case description also adds to the literature with respect
to the effect of VNS during the acute phase of NORSE. In fact, in the first case
VNS likely contributed controlling status epilepticus acutely, however, the current
evidence supporting its use is poor.
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Table 1. Clinical features, diagnostic investigations, and treatment during NORSE and
Epilepsy after NORSE
PHASE 1: NO RSE
Current Age / Age at onset
(years)
Etiology

Patient 1
39 / 37

Patient 2
44 / 33

Unknown

NORSE duration
Serum and CSF studies
- Infectious

37 days

Encephalitis anti-NMDAR no tumor
associated
42 days

- Inflammatory/immune

- Paraneoplastic

CSF(a): Encephalitis panel, bacterial and
fungal culture: Negative
Serum: Hepatitis, HIV, VDRL, CMV:
Negative
CSF: Autoimmune panel: negative.
Serum: Autoimmune panel, ANA, Anti
dsDNA, anti-nucleosomes, anti-histones, anti
DFS70, ANCA, anti-tiroglobuline,
Rheumatoid factor: Negative
CSF (Neoplastic cytology): Negative
CT (T horax-Abdomen-Pelvis) and Ultrasound
(abdomen, pelvis) were negative for tumor

- MRI findings

-At onset: Negative
-During NORSE: Hypersignal in FLAIR in the
left mesial temporal lobe and left insular white
matter
- 1.5 Years after, the abnormal signal
disappeared

EEG findings

Continuous multifocal spikes and polyspikes
(maximum right posterior temporal region)

T reatment
- ASM
- Anesthetics
- Antimicrobials
- Immunomodulatory agents
- VNS

PHASE II: Epile psy after
NO RSE
Current Age / Age at onset
(years)
Latent period after NORSE
Seizure Classification

EEG findings

CSF (b): Encephalitis panel, bacterial and
fungal culture, VDRL: Negative
Serum: Hepatitis, HIV, VDRL, Lyme, CMV:
Negative
CSF: Autoimmune panel: anti-NMDA
positive.
Serum: ANA, anti dsDNA, anti-ENA, ANCA,
Rheumatoid factor: Negative
CSF (Neoplastic cytology): Negative.
CT (T horax-Abdomen-Pelvis) and Ultrasound
(scrotum, thyroid, abdomen) were negative for
tumor.
-At onset: Negative
-During NORSE: Hypersignal in FLAIR in
bilateral mesial temporal lobe, left occipital
and splenium
-At discharge from hospital: Subtle signal
change in the left hippocampus and small
residual signal in splenium
Burst suppression pattern with multifocal
spikes (left temporal, left frontal, right
frontocentral and bifrontal)

PHT , LEV, LCM, CLB, PB, VPA, PER, LZP
Midazolam, Ketamine, Propofol

PHT , PB, LEV
Midazolam, Fentanyl, Ketamine, Propofol

Acyclovir, Ceftriaxone, Vancomycin,
Piperacilin/tazobactam (partial treatment)
Methylprednisolone, IVIG, Rituximab (6
doses-weekly), azathioprine (maintenance
therapy)
Cessation of NORSE was 7 days after VNS
was implanted:
Day 0: OC=0.25 mA, F=20Hz, PW= 250µsec,
ON=30s, OFF=30 min
Day 1: OC=1.0 mA, F=20Hz, PW= 250µsec,
ON=30s, OFF=30 min
Day 2: OC=1.25 mA, F=20Hz, PW= 250µsec,
ON=30s, OFF=30 min
Day 7: OC=1.75 mA, F=20Hz, PW= 250µsec,
ON=30s, OFF=30 min
Patient 1

Acyclovir, Vancomycin,
Piperacilin/tazobactam (Partial course)
Methylprednisolone (followed by
Prednisone), azathioprine (maintenance
therapy)
Implanted after NORSE was controlled.

39 / 37

44 / 33

No
T ype 1: focal impair awareness non-motor
seizures to bilateral tonic clonic seizures: déjà
vu/ hear voices and sounds  behavioral
arrest  eyes deviation to the left  left
facial asymmetry  left arm dystonia 
head and eyes deviation to the right 
sometimes bilateral clonic movements.
T ype 2: strange sensation  touches her head
 smiling  whistling  speak some
words with a bit delayed in reacting.
Interictal: Multifocal independent spikes
augmented during sleep (almost 2 years after
NORSE).

8 months
T ype 1: focal impair awareness non-motor
seizures: behavioral arrest  staring  loss
of awareness  right hand automatisms
/dystonic posture of the left hand.
(T ype 1 sometime progress to bilateral tonicclonic).

Patient 2

Inter Ictal: Independent bitemporal spikes,
maximum right (8 years after NORSE)

Epilepsy Classification
Etiology

Ictal: onset changes among seizures with the
majority over right posterior temporal region
and a few over left temporal region (almost 2
years after NORSE).
Slightly increased T 2 signal is present in both
hippocampi. The abnormal signal in left
insular region disappeared (almost 2 years
after NORSE).
Multi Focal Epilepsy
Unknown

Past ASM

PHT , LEV, LCM, CLB, PB, VPA, PER, LZP

Current ASM
Other treatment

LEV, LCM, PER, ESL
Immunotherapy: Azathioprine 150 mg/d since
NORSE
Implanted at 30 days after NORSE (cessation
of SRSE occurred 7 days after VNS was
implanted)
N.A.

PB, VPA, T PM, LTG
None

1 month: Up to 5 (2.5)
3 months: 1-2 per day (2)
6 months: 1-2 per day (2)
12 months: 1-3 per day (2)
18 months: 1-3 per day (2.25)
22 months: 1-3 per day (3)
24 months: 1-3 per day (3)
Mild to severe generalized impairments across
all cognitive domains (Neuropsychological
evaluation).

3 months: 15 per month (0.85)
6 months: 10 per month (1.75)
8 months: 2-3 months (2)
12 months: 2 months (2)
18 months: 2-3 month (2)
21 months: 12 per month (2.75)
24 months:8-12 per month (3)
Multifocal Cognitive Impairment. Probably
non-dominant (more likely right) mesial
temporal impairment and frontal dysfunction
(not clearly lateralized). Dominant temporal
impairment (more likely left) not ruled out.
No evidence of depression or any other mood
disturbance.

MRI findings

VNS
Frequency of seizures
before VNS
Frequency of seizures
after VNS
(Output current mA)

Cognitive Outcome

Emotional Outcome
Social Outcome

Mild symptoms of depression and anxiety
(She took antidepressants when symptoms
were severe)
She is unable to carry out all of her previous
activities but is able to take care of her own
affairs without help. She works from home as
a writer of educational material.

Ictal: Onset over left temporal region mostly
and over right temporal region in a lesser
degree (3 years after NORSE).
Bilateral hippocampal atrophy and T2
hyperintense signal abnormality. Resolution
of signal abnormality in splenium (9 years
after NORSE).
Independent Bi T emporal Epilepsy
Structural (Bilateral MTS) / “ Autoimmuneassociated”
LCS, ESL, PER, PHT, BRV

Implanted 9 years after NORSE
12 per month

Not currently working as truck driver. He is
on a disability support program

Cytochemical study in CSF showed mild pleocytosis: a:14 cel; b: 20 cel (lymphocyte predominance)
Encephalitis panel: Herpes Simple Virus I-II, varicella zoster, and enterovirus RNA
Autoimmune panel: Anti-AMPA, anti-CASPR, anti DPPX, anti-GABA antibody, anti-LGI1, anti-NMDA, anti-GAD65, anti IgLON5
NMDAR: N-methyl-D-aspartate receptor; CSF: cerebrospinal fluid; HIV: human immunodeficiency virus; VDRL: test for syphilis;
CMV: Cytomegalovirus; ANA: Antinuclear antibodies; dsDNA: double stranded DNA; ANA: Nuclear Antigen Antibodies, ANCA:
Antineutrophil cytoplasmic antibody; CT : Computerized tomography; MRI: magnetic resonance imaging; EEG:
electroencephalogram; ASM: anti-seizure medication; PHT: phenytoin; LEV: Levetiracetam; LCM: lacosamide; CLB; clobazam; PB:
phenobarbital; VPA: valproic acid; PER: perampanel; LZP: Lorazepam; ESL: eslicarbazepine; BRV: brivaracetam; TPM: topiramate,
LT G: lamotrigine; IVIG: Intravenous Immunoglobulin; MTS: mesial temporal sclerosis; VNS: Vagus nerve stimulator; SRSE: super
refractory status epilepticus; N.A: not applicable.

Figure 1. Bilateral mesial temporal sclerosis and left temporo-occipital cortical atrophy
were seen in Patient 2. Coronal FLAIR MRI showing bilateral atrophy and hyper signal
in both hippocampi (white arrows) (A). Axial T2 MRI shows important cortical atrophy
especially in the left posterior quadrant (red asterisks) (B). R (right); L (left); P (posterior).
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